Raquel Sanchez-Valle

List of Publications by Year in Descending Order

269 papers	7,819 citations	47 h-index	79 g-index
313 ext. papers	10,208 ext. citations	6.2 avg, IF	5.44 L-index

#	Paper	IF	Citations
269	Cognitive composites for genetic frontotemporal dementia: GENFI-Cog.. *Alzheimer's Research and Therapy*, **2022**, 14, 10	9	0
268	Cortical microstructure in primary progressive aphasia: a multicenter study.. *Alzheimer's Research and Therapy*, **2022**, 14, 27	9	0
267	Examining empathy deficits across familial forms of frontotemporal dementia within the GENFI cohort.. *Cortex*, **2022**, 150, 12-28	3.8	
266	Data-driven staging of genetic frontotemporal dementia using multi-modal MRI.. *Human Brain Mapping*, **2022**,	5.9	1
265	Diagnostic accuracy of cerebrospinal fluid biomarkers in genetic prion diseases.. *Brain*, **2022**,	11.2	1
264	Anomia is present pre-symptomatically in frontotemporal dementia due to MAPT mutations.. *Journal of Neurology*, **2022**, 1	5.5	
263	A neurodegenerative disease landscape of rare mutations in Colombia due to founder effects.. *Genome Medicine*, **2022**, 14, 27	14.4	1
262	Development of a sensitive trial-ready poly(GP) CSF biomarker assay for -associated frontotemporal dementia and amyotrophic lateral sclerosis.. *Journal of Neurology, Neurosurgery and Psychiatry*, **2022**,	5.5	2
261	New insights into the genetic etiology of Alzheimer's disease and related dementias.. *Nature Genetics*, **2022**,	36.3	27
260	CSF Biomarkers in COVID-19 Associated Encephalopathy and Encephalitis Predict Long-Term Outcome.. *Frontiers in Immunology*, **2022**, 13, 866153	8.4	2
259	Homozygous R136S mutation in PRNP gene causes inherited early onset prion disease. *Alzheimer's Research and Therapy*, **2021**, 13, 176	9	2
258	Sex differences in the behavioral variant of frontotemporal dementia: A new window to executive and behavioral reserve. *Alzheimer's and Dementia*, **2021**, 17,	1.2	3
257	Conceptual framework for the definition of preclinical and prodromal frontotemporal dementia. *Alzheimer's and Dementia*, **2021**,	1.2	2
256	Stratifying the Presymptomatic Phase of Genetic Frontotemporal Dementia by Serum NfL and pNfH: A Longitudinal Multicentre Study. *Annals of Neurology*, **2021**,	9.4	2
255	Homozygous R136S mutation in PRNP gene causes inherited early onset prion disease. *Alzheimer's Research and Therapy*, **2021**, 13, 176	9	1
254	A panel of CSF proteins separates genetic frontotemporal dementia from presymptomatic mutation carriers: a GENFI study. *Molecular Neurodegeneration*, **2021**, 16, 79	19	0
253	Baseline MRI atrophy predicts 2-year cognitive outcomes in early-onset Alzheimer's disease. *Journal of Neurology*, **2021**, 1	5.5	0

252	A data-driven disease progression model of fluid biomarkers in genetic frontotemporal dementia. *Brain*, **2021**,	11.2	3
251	Prion diseases. *European Neuropsychopharmacology*, **2021**, 55, 1-3	1.2	
250	Detection of -synuclein in CSF by RT-QuIC in patients with isolated rapid-eye-movement sleep behaviour disorder: a longitudinal observational study. *Lancet Neurology, The*, **2021**, 20, 203-212	24.1	52
249	MRI data-driven algorithm for the diagnosis of behavioural variant frontotemporal dementia. *Journal of Neurology, Neurosurgery and Psychiatry*, **2021**,	5.5	3
248	Diagnostic Utility of Measuring Cerebral Atrophy in the Behavioral Variant of Frontotemporal Dementia and Association With Clinical Deterioration. *JAMA Network Open*, **2021**, 4, e211290	10.4	3
247	CSF sTREM2 is elevated in a subset in GRN-related frontotemporal dementia. *Neurobiology of Aging* , **2021**, 103, 158.e1-158.e5	5.6	2
246	TREM2 expression in the brain and biological fluids in prion diseases. *Acta Neuropathologica*, **2021**, 141, 841-859	14.3	5
245	Accelerated long-term forgetting in individuals with subjective cognitive decline and amyloid- positivity. *International Journal of Geriatric Psychiatry*, **2021**, 36, 1037-1049	3.9	2
244	Plasma Neurofilament Light for Prediction of Disease Progression in Familial Frontotemporal Lobar Degeneration. *Neurology*, **2021**, 96, e2296-e2312	6.5	12
243	Characterizing the Clinical Features and Atrophy Patterns of -Related Frontotemporal Dementia With Disease Progression Modeling. *Neurology*, **2021**, 97, e941-e952	6.5	3
242	Common variants in Alzheimer's disease and risk stratification by polygenic risk scores. *Nature Communications*, **2021**, 12, 3417	17.4	23
241	Multi-cohort profiling reveals elevated CSF levels of brain-enriched proteins in Alzheimer's disease. *Annals of Clinical and Translational Neurology*, **2021**, 8, 1456-1470	5.3	3
240	A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease. *Nature Medicine*, **2021**, 27, 1187-1196	50.5	51
239	The Revised Self-Monitoring Scale detects early impairment of social cognition in genetic frontotemporal dementia within the GENFI cohort. *Alzheimer's Research and Therapy*, **2021**, 13, 127	9	2
238	Genetic variation in APOE, GRN, and TP53 are phenotype modifiers in frontotemporal dementia. *Neurobiology of Aging*, **2021**, 99, 99.e15-99.e22	5.6	3
237	Biphasic cortical macro- and microstructural changes in autosomal dominant Alzheimer's disease. *Alzheimer's and Dementia*, **2021**, 17, 618-628	1.2	11
236	Brain functional network integrity sustains cognitive function despite atrophy in presymptomatic genetic frontotemporal dementia. *Alzheimer's and Dementia*, **2021**, 17, 500-514	1.2	8
235	Presentations and mechanisms of CNS disorders related to COVID-19. *Neurology: Neuroimmunology and NeuroInflammation*, **2021**, 8,	9.1	28

234	Errorless Learning Therapy in Semantic Variant of Primary Progressive Aphasia. *Journal of Alzheimer's Disease*, **2021**, 79, 415-422	4.3	2
233	Apathy in presymptomatic genetic frontotemporal dementia predicts cognitive decline and is driven by structural brain changes. *Alzheimer's and Dementia*, **2021**, 17, 969-983	1.2	9
232	Progression of Behavioral Disturbances and Neuropsychiatric Symptoms in Patients With Genetic Frontotemporal Dementia. *JAMA Network Open*, **2021**, 4, e2030194	10.4	14
231	Modelling the cascade of biomarker changes in -related frontotemporal dementia. *Journal of Neurology, Neurosurgery and Psychiatry*, **2021**, 92, 494-501	5.5	11
230	Cognitive decline in amyotrophic lateral sclerosis: Neuropathological substrate and genetic determinants. *Brain Pathology*, **2021**, 31, e12942	6	1
229	Sex differences in the behavioral variant of frontotemporal dementia: A new window to executive and behavioral reserve. *Alzheimer's and Dementia*, **2021**, 17, 1329-1341	1.2	10
228	Pioglitazone for prevention of cognitive impairment: results and lessons. *Lancet Neurology, The*, **2021**, 20, 500-502	24.1	0
227	Practice effects in genetic frontotemporal dementia and at-risk individuals: a GENFI study. *Journal of Neurology, Neurosurgery and Psychiatry*, **2021**,	5.5	
226	Dissemination in time and space in presymptomatic granulin mutation carriers: a GENFI spatial chronnectome study. *Neurobiology of Aging*, **2021**, 108, 155-167	5.6	0
225	Neuroanatomical and cognitive correlates of visual hallucinations in Parkinson's disease and dementia with Lewy bodies: Voxel-based morphometry and neuropsychological meta-analysis. *Neuroscience and Biobehavioral Reviews*, **2021**, 128, 367-382	9	3
224	Differential early subcortical involvement in genetic FTD within the GENFI cohort. *NeuroImage: Clinical*, **2021**, 30, 102646	5.3	6
223	Disease-related cortical thinning in presymptomatic granulin mutation carriers. *NeuroImage: Clinical* , **2021**, 29, 102540	5.3	2
222	Longitudinal brain atrophy and CSF biomarkers in early-onset Alzheimer's disease. *NeuroImage: Clinical*, **2021**, 32, 102804	5.3	3
221	SLITRK2, an X-linked modifier of the age at onset in C9orf72 frontotemporal lobar degeneration. *Brain*, **2021**, 144, 2798-2811	11.2	2
220	Accelerated long-term forgetting over three months in asymptomatic APOE e4 carriers. *Annals of Clinical and Translational Neurology*, **2021**, 8, 477-484	5.3	5
219	ALTOIDA-iADL for the diagnosis of Mild Cognitive Impairment and early Alzheimer's disease.. *Alzheimer's and Dementia*, **2021**, 17 Suppl 12, e057982	1.2	
218	Impact of COVID-19 pandemic in an early-onset dementia clinic in Barcelona.. *Alzheimer's and Dementia*, **2021**, 17 Suppl 7, e052114	1.2	
217	Functional network alterations in early-onset Alzheimer's disease studied with resting-state fMRI. *Alzheimer's and Dementia*, **2020**, 16, e043307	1.2	

216	Telemedicine assessment of long-term cognitive and functional status in anti-leucine-rich, glioma-inactivated 1 encephalitis. *Neurology: Neuroimmunology and NeuroInflammation*, **2020**, 7,	9.1	13
215	Autoantibodies against the prion protein in individuals with mutations. *Neurology*, **2020**, 95, e2028-e2037	7.5	5
214	A modified Camel and Cactus Test detects presymptomatic semantic impairment in genetic frontotemporal dementia within the GENFI cohort. *Applied Neuropsychology Adult*, **2020**, 1-8	1.9	8
213	Plasma glial fibrillary acidic protein is raised in progranulin-associated frontotemporal dementia. *Journal of Neurology, Neurosurgery and Psychiatry*, **2020**, 91, 263-270	5.5	40
212	Diagnostic Accuracy of MRI Visual Rating Scales in the Diagnosis of Early Onset Cognitive Impairment. *Journal of Alzheimer's Disease*, **2020**, 73, 1575-1583	4.3	9
211	Contribution of CSF biomarkers to early-onset Alzheimer's disease and frontotemporal dementia neuroimaging signatures. *Human Brain Mapping*, **2020**, 41, 2004-2013	5.9	8
210	Neuronal pentraxin 2: a synapse-derived CSF biomarker in genetic frontotemporal dementia. *Journal of Neurology, Neurosurgery and Psychiatry*, **2020**, 91, 612-621	5.5	22
209	Screening of dementia genes by whole-exome sequencing in Spanish patients with early-onset dementia: likely pathogenic, uncertain significance and risk variants. *Neurobiology of Aging*, **2020**, 93, e1-e9	5.6	4
208	Social cognition impairment in genetic frontotemporal dementia within the GENFI cohort. *Cortex*, **2020**, 133, 384-398	3.8	7
207	Synaptic, axonal damage and inflammatory cerebrospinal fluid biomarkers in neurodegenerative dementias. *Alzheimer's and Dementia*, **2020**, 16, 262-272	1.2	29
206	Role for ATXN1, ATXN2, and HTT intermediate repeats in frontotemporal dementia and Alzheimer's disease. *Neurobiology of Aging*, **2020**, 87, 139.e1-139.e7	5.6	13
205	Multicenter Alzheimer's and Parkinson's disease immune biomarker verification study. *Alzheimer's and Dementia*, **2020**, 16, 292-304	1.2	16
204	Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study. *Lancet Neurology, The*, **2020**, 19, 145-156	24.1	90
203	Sex Differences of Longitudinal Brain Changes in Cognitively Unimpaired Adults. *Journal of Alzheimer's Disease*, **2020**, 76, 1413-1422	4.3	1
202	Use of Antipsychotics in Patients with Behavioral and Psychological Symptoms of Dementia: Results of a Spanish Delphi Consensus. *Dementia and Geriatric Cognitive Disorders*, **2020**, 49, 573-582	2.6	1
201	LifeTime and improving European healthcare through cell-based interceptive medicine. *Nature*, **2020**, 587, 377-386	50.4	56
200	Early symptoms in symptomatic and preclinical genetic frontotemporal lobar degeneration. *Journal of Neurology, Neurosurgery and Psychiatry*, **2020**, 91, 975-984	5.5	15
199	Abnormal pain perception is associated with thalamo-cortico-striatal atrophy in expansion carriers in the GENFI cohort. *Journal of Neurology, Neurosurgery and Psychiatry*, **2020**, 91, 1325-1328	5.5	5

198	Effects of IgLON5 Antibodies on Neuronal Cytoskeleton: A Link between Autoimmunity and Neurodegeneration. *Annals of Neurology*, **2020**, 88, 1023-1027	9.4	25
197	, age at onset, and ancestry help discriminate behavioral from language variants in FTLD cohorts. *Neurology*, **2020**, 95, e3288-e3302	6.5	5
196	Digital biomarker-based individualized prognosis for people at risk of dementia. *Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring*, **2020**, 12, e12073	5.2	9
195	Analysis of brain atrophy and local gene expression in genetic frontotemporal dementia. *Brain Communications*, **2020**, 2,	4.5	6
194	Faster Cortical Thinning and Surface Area Loss in Presymptomatic and Symptomatic C9orf72 Repeat Expansion Adult Carriers. *Annals of Neurology*, **2020**, 88, 113-122	9.4	11
193	Microglial Hyperreactivity Evolved to Immunosuppression in the Hippocampus of a Mouse Model of Accelerated Aging and Alzheimer's Disease Traits. *Frontiers in Aging Neuroscience*, **2020**, 12, 622360	5.3	1
192	Evolution of Clinical-Pathological Correlations in Early-Onset Alzheimer's Disease Over a 25-Year Period in an Academic Brain Bank. *Journal of Alzheimer's Disease*, **2020**, 1-11	4.3	0
191	Early detection of subtle motor dysfunction in cognitively normal subjects with amyloid-β positivity. *Cortex*, **2019**, 121, 117-124	3.8	3
190	The inner fluctuations of the brain in presymptomatic Frontotemporal Dementia: The chronnectome fingerprint. *NeuroImage*, **2019**, 189, 645-654	7.9	18
189	Tau Protein is Associated with Longitudinal Memory Decline in Cognitively Healthy Subjects with Normal Alzheimer's Disease Cerebrospinal Fluid Biomarker Levels. *Journal of Alzheimer's Disease*, **2019**, 70, 211-225	4.3	6
188	Clinical value of cerebrospinal fluid neurofilament light chain in semantic dementia. *Journal of Neurology, Neurosurgery and Psychiatry*, **2019**, 90, 997-1004	5.5	13
187	Education modulates brain maintenance in presymptomatic frontotemporal dementia. *Journal of Neurology, Neurosurgery and Psychiatry*, **2019**, 90, 1124-1130	5.5	10
186	Regional patterns of 18F-florbetaben uptake in presenilin 1 mutation carriers. *Neurobiology of Aging*, **2019**, 81, 1-8	5.6	4
185	Novel CSF biomarkers in genetic frontotemporal dementia identified by proteomics. *Annals of Clinical and Translational Neurology*, **2019**, 6, 698-707	5.3	25
184	Cortical microstructure in the behavioural variant of frontotemporal dementia: looking beyond atrophy. *Brain*, **2019**, 142, 1121-1133	11.2	32
183	Mechanisms of functional compensation, delineated by eigenvector centrality mapping, across the pathophysiological continuum of Alzheimer's disease. *NeuroImage: Clinical*, **2019**, 22, 101777	5.3	17
182	Comparison of Pittsburgh compound B and florbetapir in cross-sectional and longitudinal studies. *Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring*, **2019**, 11, 180-190	5.2	46
181	CSF glial biomarkers YKL40 and sTREM2 are associated with longitudinal volume and diffusivity changes in cognitively unimpaired individuals. *NeuroImage: Clinical*, **2019**, 23, 101801	5.3	17

180	Clinical and video-polysomnographic analysis of rapid eye movement sleep behavior disorder and other sleep disturbances in dementia with Lewy bodies. *Sleep*, **2019**, 42,	1.1	13
179	Clinical applicability of diagnostic biomarkers in early-onset cognitive impairment. *European Journal of Neurology*, **2019**, 26, 1098-1104	6	11
178	Cerebrospinal Fluid Total Prion Protein in the Spectrum of Prion Diseases. *Molecular Neurobiology*, **2019**, 56, 2811-2821	6.2	16
177	Hippocampal atrophy has limited usefulness as a diagnostic biomarker on the early onset Alzheimer's disease patients: A comparison between visual and quantitative assessment. *NeuroImage: Clinical*, **2019**, 23, 101927	5.3	18
176	Novel P397S MAPT variant associated with late onset and slow progressive frontotemporal dementia. *Annals of Clinical and Translational Neurology*, **2019**, 6, 1559-1565	5.3	3
175	A unique common ancestor introduced P301L mutation in MAPT gene in frontotemporal dementia patients from Barcelona (Baix Llobregat, Spain). *Neurobiology of Aging*, **2019**, 84, 236.e9-236.e15	5.6	6
174	Serum neurofilament light chain in genetic frontotemporal dementia: a longitudinal, multicentre cohort study. *Lancet Neurology, The*, **2019**, 18, 1103-1111	24.1	68
173	IC-02-05: GENDER DIFFERENCES IN THE ASSOCIATION BETWEEN LONGITUDINAL BRAIN CHANGES AND BASELINE LEVELS OF CSF ALZHEIMER'S DISEASE AND GLIAL BIOMARKERS IN HEALTHY ELDERS **2019**, 15, P4-P4		
172	Plasma levels of soluble TREM2 and neurofilament light chain in TREM2 rare variant carriers. *Alzheimer's Research and Therapy*, **2019**, 11, 94	9	15
171	APP-derived peptides reflect neurodegeneration in frontotemporal dementia. *Annals of Clinical and Translational Neurology*, **2019**, 6, 2518-2530	5.3	10
170	White matter hyperintensities in progranulin-associated frontotemporal dementia: A longitudinal GENFI study. *NeuroImage: Clinical*, **2019**, 24, 102077	5.3	13
169	Evaluation of Human Cerebrospinal Fluid Malate Dehydrogenase 1 as a Marker in Genetic Prion Disease Patients. *Biomolecules*, **2019**, 9,	5.9	4
168	CSF-ApoER2 fragments as a read-out of reelin signaling: Distinct patterns in sporadic and autosomal-dominant Alzheimer disease. *Clinica Chimica Acta*, **2019**, 490, 6-11	6.2	1
167	Changes in Synaptic Proteins Precede Neurodegeneration Markers in Preclinical Alzheimer's Disease Cerebrospinal Fluid. *Molecular and Cellular Proteomics*, **2019**, 18, 546-560	7.6	66
166	Does ALS-FUS without FUS mutation represent ALS-FET? Report of three cases. *Neuropathology and Applied Neurobiology*, **2019**, 45, 421-426	5.2	3
165	Challenges associated with biomarker-based classification systems for Alzheimer's disease. *Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring*, **2018**, 10, 346-357	5.2	25
164	Poly(GP), neurofilament and grey matter deficits in expansion carriers. *Annals of Clinical and Translational Neurology*, **2018**, 5, 583-597	5.3	29
163	Cerebrospinal fluid neurofilament light levels in neurodegenerative dementia: Evaluation of diagnostic accuracy in the differential diagnosis of prion diseases. *Alzheimer's and Dementia*, **2018**, 14, 751-763	1.2	45

162	Structural Connectivity Alterations Along the Alzheimer's Disease Continuum: Reproducibility Across Two Independent Samples and Correlation with Cerebrospinal Fluid Amyloid-β and Tau. *Journal of Alzheimer's Disease*, **2018**, 61, 1575-1587	4.3	20
161	Tauopathy with Hippocampal 4-Repeat Tau Immunoreactive Spherical Inclusions in a Patient with PSP. *Brain Pathology*, **2018**, 28, 284-286	6	2
160	Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study. *Lancet Neurology, The*, **2018**, 17, 548-558	24.1	60
159	Rare nonsynonymous variants in SORT1 are associated with increased risk for frontotemporal dementia. *Neurobiology of Aging*, **2018**, 66, 181.e3-181.e10	5.6	12
158	Validation of α-Synuclein as a CSF Biomarker for Sporadic Creutzfeldt-Jakob Disease. *Molecular Neurobiology*, **2018**, 55, 2249-2257	6.2	30
157	Interrupted CAG expansions in ATXN2 gene expand the genetic spectrum of frontotemporal dementias. *Acta Neuropathologica Communications*, **2018**, 6, 41	7.3	10
156	The hippocampal longitudinal axis-relevance for underlying tau and TDP-43 pathology. *Neurobiology of Aging*, **2018**, 70, 1-9	5.6	15
155	Systematic Screening of Ubiquitin/p62 Aggregates in Cerebellar Cortex Expands the Neuropathological Phenotype of the C9orf72 Expansion Mutation. *Journal of Neuropathology and Experimental Neurology*, **2018**, 77, 703-709	3.1	8
154	No supportive evidence for TIA1 gene mutations in a European cohort of ALS-FTD spectrum patients. *Neurobiology of Aging*, **2018**, 69, 293.e9-293.e11	5.6	11
153	Common and rare TBK1 variants in early-onset Alzheimer disease in a European cohort. *Neurobiology of Aging*, **2018**, 62, 245.e1-245.e7	5.6	12
152	P2-347: THE HIPPOCAMPAL LONGITUDINAL AXIS: RELEVANCE FOR UNDERLYING TAU AND TDP-43 PATHOLOGY **2018**, 14, P819-P820		
151	P1-146: WHOLE EXOME SEQUENCING IN PATIENTS WITH EARLY-ONSET ALZHEIMER'S DISEASE AND FRONTOTEMPORAL DEMENTIA: MUTATION DETECTION IN CAUSAL AND RISK GENES FOR DEMENTIA **2018**, 14, P332-P332		
150	P2-262: A CEREBROSPINAL FLUID PANEL OF SYNAPTIC PROTEINS ACROSS THE ENTIRE ALZHEIMER'S DISEASE CONTINUUM **2018**, 14, P777-P777		
149	P3-394: CORTICAL MEAN DIFFUSIVITY MAY BE MORE SENSITIVE IN DETECTING STRUCTURAL CHANGES IN FRONTOTEMPORAL DEMENTIA THAN CORTICAL THICKNESS **2018**, 14, P1248-P1249		
148	P1-432: REGIONAL PATTERNS OF 18F-FLORBETABEN UPTAKE IN PRESENILIN 1´MUTATION CARRIERS **2018**, 14, P475-P475		
147	O3-09-03: SERUM NEUROFILAMENT LIGHT LEVELS CORRELATE WITH SEVERITY MEASURES AND NEURODEGENERATION MARKERS IN AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE **2018**, 14, P1037-P1037		
146	Serum neurofilament light levels correlate with severity measures and neurodegeneration markers in autosomal dominant Alzheimer's disease. *Alzheimer's Research and Therapy*, **2018**, 10, 113	9	38
145	Prevalence of amyloid-β pathology in distinct variants of primary progressive aphasia. *Annals of Neurology*, **2018**, 84, 729-740	9.4	74

144	Variably protease-sensitive prionopathy presenting within ALS/FTD spectrum. *Annals of Clinical and Translational Neurology*, **2018**, 5, 1297-1302	5.3	8
143	P2-230: CHALLENGES ASSOCIATED WITH BIOMARKER-BASED CLASSIFICATIONS SYSTEMS FOR ALZHEIMER'S DISEASE **2018**, 14, P756-P757		
142	-Synuclein aggregates in labial salivary glands of idiopathic rapid eye movement sleep behavior disorder. *Sleep*, **2018**, 41,	1.1	12
141	Adaptation and validation of a Spanish-language version of the Frontotemporal Dementia Rating Scale (FTD-FRS). *Neurología*, **2017**, 32, 290-299	1.4	3
140	Active A-immunotherapy CAD106 in Alzheimer's disease: A phase 2b study. *Alzheimer's and Dementia: Translational Research and Clinical Interventions*, **2017**, 3, 10-22	6	65
139	The 4 genotype modulates CSF YKL-40 levels and their structural brain correlates in the continuum of Alzheimer's disease but not those of sTREM2. *Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring*, **2017**, 6, 50-59	5.2	29
138	A Common Variant in the MC1R Gene (p.V92M) is associated with Alzheimer's Disease Risk. *Journal of Alzheimer's Disease*, **2017**, 56, 1065-1074	4.3	1
137	Improved Cerebrospinal Fluid-Based Discrimination between Alzheimer's Disease Patients and Controls after Correction for Ventricular Volumes. *Journal of Alzheimer's Disease*, **2017**, 56, 543-555	4.3	7
136	Cerebral amyloid angiopathy in Down syndrome and sporadic and autosomal-dominant Alzheimer's disease. *Alzheimer's and Dementia*, **2017**, 13, 1251-1260	1.2	38
135	Deleterious ABCA7 mutations and transcript rescue mechanisms in early onset Alzheimer's disease. *Acta Neuropathologica*, **2017**, 134, 475-487	14.3	34
134	C-terminal fragments of the amyloid precursor protein in cerebrospinal fluid as potential biomarkers for Alzheimer disease. *Scientific Reports*, **2017**, 7, 2477	4.9	21
133	CSF sAPP-YKL-40, and neurofilament light in frontotemporal lobar degeneration. *Neurology*, **2017**, 89, 178-188	6.5	75
132	TBK1 Mutation Spectrum in an Extended European Patient Cohort with Frontotemporal Dementia and Amyotrophic Lateral Sclerosis. *Human Mutation*, **2017**, 38, 297-309	4.7	66
131	YKL-40 in the brain and cerebrospinal fluid of neurodegenerative dementias. *Molecular Neurodegeneration*, **2017**, 12, 83	19	86
130	Dopamine transporter imaging deficit predicts early transition to synucleinopathy in idiopathic rapid eye movement sleep behavior disorder. *Annals of Neurology*, **2017**, 82, 419-428	9.4	108
129	Frontotemporal Dementia Caused by the P301L Mutation in the MAPT Gene: Clinicopathological Features of 13 Cases from the Same Geographical Origin in Barcelona, Spain. *Dementia and Geriatric Cognitive Disorders*, **2017**, 44, 213-221	2.6	23
128	Adaptation and validation of a Spanish-language version of the Frontotemporal Dementia Rating Scale (FTD-FRS). *Neurología (English Edition)*, **2017**, 32, 290-299	0.4	0
127	[P4-07]: A PRESCREENING STUDY IN SPAIN TO IDENTIFY INDIVIDUALS WHO MIGHT BE SUITABLE FOR PARTICIPATION IN CLINICAL STUDIES IN EARLY ALZHEIMER's DISEASE UTILIZING REFERRALS FROM GENERAL PRACTITIONER NETWORKS **2017**, 13, P1345-P1346		

126	[P4189]: SYMPTOM ONSET IN GENETIC FRONTOTEMPORAL DEMENTIA **2017**, 13, P1337-P1337		1
125	Neuronal intranuclear (hyaline) inclusion disease and fragile X-associated tremor/ataxia syndrome: a morphological and molecular dilemma. *Brain*, **2017**, 140, e51	11.2	27
124	CSF microRNA Profiling in Alzheimer's Disease: a Screening and Validation Study. *Molecular Neurobiology*, **2017**, 54, 6647-6654	6.2	29
123	Plasma miR-34a-5p and miR-545-3p as Early Biomarkers of Alzheimer's Disease: Potential and Limitations. *Molecular Neurobiology*, **2017**, 54, 5550-5562	6.2	81
122	[P2410]: VISUAL AND QUANTITATIVE ASSESSMENT OF HIPPOCAMPAL ATROPHY IN EARLY ONSET ALZHEIMER's DISEASE PATIENTS **2017**, 13, P789-P789		
121	[P4214]: TOWARD A FUNCTIONAL NEUROMARKER FOR PRECLINICAL AD: EIGENVECTOR CENTRALITY REVEALS PRECLINICAL DIFFERENCES OF FUNCTIONAL INFORMATION FLOW IN THE HIPPOCAMPUS, PRECUNEUS, CEREBELLUM AND INFERIOR PARIETAL LOBULE **2017**, 13, P1348-P1349		
120	[P1413]: VISUAL PATTERNS OF FLORBETABEN UPTAKE IN PRESENILIN 1 MUTATION CARRIERS **2017**, 13, P435-P435		
119	Clinical Neuropathology image 4-2017: High-resolution 7 Tesla MRI of postmortem brain specimens: improving neuroimaging-neuropathology correlations **2017**, 36, 162-163		1
118	Quantitative Magnetic Resonance Abnormalities in Creutzfeldt-Jakob Disease and Fatal Insomnia. *Journal of Alzheimer's Disease*, **2017**, 55, 431-443	4.3	13
117	Validation of 14-3-3 Protein as a Marker in Sporadic Creutzfeldt-Jakob Disease Diagnostic. *Molecular Neurobiology*, **2016**, 53, 2189-99	6.2	65
116	Neurofilament light chain: a biomarker for genetic frontotemporal dementia. *Annals of Clinical and Translational Neurology*, **2016**, 3, 623-36	5.3	163
115	Preservation of cell-survival mechanisms by the presenilin-1 K239N mutation may cause its milder clinical phenotype. *Neurobiology of Aging*, **2016**, 46, 169-79	5.6	3
114	Cerebrospinal fluid sTREM2 levels are associated with gray matter volume increases and reduced diffusivity in early Alzheimer's disease. *Alzheimer's and Dementia*, **2016**, 12, 1259-1272	1.2	67
113	Cerebrospinal Fluid Biomarkers Predict Clinical Evolution in Patients with Subjective Cognitive Decline and Mild Cognitive Impairment. *Neurodegenerative Diseases*, **2016**, 16, 69-76	2.3	34
112	Assessing the role of TUBA4A gene in frontotemporal degeneration. *Neurobiology of Aging*, **2016**, 38, 215.e13-215.e14	5.6	7
111	CSF YKL-40 and pTau181 are related to different cerebral morphometric patterns in early AD. *Neurobiology of Aging*, **2016**, 38, 47-55	5.6	42
110	Altered Blood Gene Expression of Tumor-Related Genes (PRKCB, BECN1, and CDKN2A) in Alzheimer's Disease. *Molecular Neurobiology*, **2016**, 53, 5902-5911	6.2	9
109	Sporadic MM2-thalamic + cortical Creutzfeldt-Jakob disease: Utility of diffusion tensor imaging in the detection of cortical involvement in vivo. *Neuropathology*, **2016**, 36, 199-204	2	9

108	sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer's disease and associate with neuronal injury markers. *EMBO Molecular Medicine*, **2016**, 8, 466-76	12	256
107	White Matter Abnormalities Track Disease Progression in PSEN1 Autosomal Dominant Alzheimer's Disease. *Journal of Alzheimer's Disease*, **2016**, 51, 827-35	4.3	12
106	IC-02-05: Cerebrospinal Fluid Strem2 Levels are Associated with Gray Matter Volume Increases and Reduced Diffusivity in Early Alzheimer's Disease **2016**, 12, P8-P8		
105	A comprehensive study of the genetic impact of rare variants in SORL1 in European early-onset Alzheimer's disease. *Acta Neuropathologica*, **2016**, 132, 213-224	14.3	62
104	Cerebrospinal fluid Presenilin-1 increases at asymptomatic stage in genetically determined Alzheimer's disease. *Molecular Neurodegeneration*, **2016**, 11, 66	19	6
103	Gerstmann-Sträussler-Scheinker Disease Presenting with Atypical Parkinsonism, but Typical Magnetic Resonance Imaging Findings of Prion Disease. *Movement Disorders Clinical Practice*, **2016**, 3, 93-95	2.2	4
102	Analysis of the CHCHD10 gene in patients with frontotemporal dementia and amyotrophic lateral sclerosis from Spain. *Brain*, **2015**, 138, e400	11.2	47
101	Genetic variability in SQSTM1 and risk of early-onset Alzheimer dementia: a European early-onset dementia consortium study. *Neurobiology of Aging*, **2015**, 36, 2005.e15-22	5.6	29
100	O3-13-06: Targeted re-sequencing of sorl1 in early-onset Alzheimer's dementia: The european early onset dementia consortium **2015**, 11, P253-P253		
99	Rare Variants in PLD3 Do Not Affect Risk for Early-Onset Alzheimer Disease in a European Consortium Cohort. *Human Mutation*, **2015**, 36, 1226-35	4.7	20
98	Clinicopathological Correlations and Concomitant Pathologies in Rapidly Progressive Dementia: A Brain Bank Series. *Neurodegenerative Diseases*, **2015**, 15, 350-60	2.3	27
97	Diagnostic accuracy of behavioral variant frontotemporal dementia consortium criteria (FTDC) in a clinicopathological cohort. *Neuropathology and Applied Neurobiology*, **2015**, 41, 882-92	5.2	21
96	Evolving brain structural changes in PSEN1 mutation carriers. *Neurobiology of Aging*, **2015**, 36, 1261-70	5.6	27
95	Rapidly progressive dementia with psychotic onset in a patient with the C9ORF72 mutation **2015**, 34, 294-7		6
94	TMEM106B is a genetic modifier of frontotemporal lobar degeneration with C9orf72 hexanucleotide repeat expansions. *Acta Neuropathologica*, **2014**, 127, 407-18	14.3	97
93	Large APP locus duplication in a sporadic case of cerebral haemorrhage. *Neurogenetics*, **2014**, 15, 145-9	3	7
92	Characterization of the repeat expansion size in C9orf72 in amyotrophic lateral sclerosis and frontotemporal dementia. *Human Molecular Genetics*, **2014**, 23, 749-54	5.6	84
91	Plasma phosphorylated TDP-43 levels are elevated in patients with frontotemporal dementia carrying a C9orf72 repeat expansion or a GRN mutation. *Journal of Neurology, Neurosurgery and Psychiatry*, **2014**, 85, 684-91	5.5	47

90	Cerebrospinal fluid level of YKL-40 protein in preclinical and prodromal Alzheimer's disease. *Journal of Alzheimer's Disease*, **2014**, 42, 901-8	4.3	79
89	Investigation of the role of rare TREM2 variants in frontotemporal dementia subtypes. *Neurobiology of Aging*, **2014**, 35, 2657.e13-2657.e19	5.6	31
88	Rare mutations in SQSTM1 modify susceptibility to frontotemporal lobar degeneration. *Acta Neuropathologica*, **2014**, 128, 397-410	14.3	83
87	O4-11-04: ACTIVE A□IMMUNOTHERAPY CAD106 PHASE II DOSE-ADJUVANT FINDING STUDY: SAFETY AND CNS BIOMARKERS **2014**, 10, P274-P274		2
86	Usefulness of biomarkers in the diagnosis and prognosis of early-onset cognitive impairment. *Journal of Alzheimer's Disease*, **2014**, 40, 919-27	4.3	27
85	Determination of neuronal antibodies in suspected and definite Creutzfeldt-Jakob disease. *JAMA Neurology*, **2014**, 71, 74-8	17.2	43
84	In vivo decreased dopamine transporter uptake in corticobasal degeneration presenting with primary progressive aphasia without parkinsonism. *European Journal of Neurology*, **2014**, 21, e56-7	6	1
83	Reply: To PMID 23794434. *Annals of Neurology*, **2014**, 75, 460-1	9.4	
82	TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis. *Science Translational Medicine*, **2014**, 6, 243ra86	17.5	436
81	Assessing the role of the TREM2 p.R47H variant as a risk factor for Alzheimer's disease and frontotemporal dementia. *Neurobiology of Aging*, **2014**, 35, 444.e1-4	5.6	81
80	TARDBP mutation p.Ile383Val associated with semantic dementia and complex proteinopathy. *Neuropathology and Applied Neurobiology*, **2014**, 40, 225-30	5.2	36
79	Neurodegenerative disorder risk in idiopathic REM sleep behavior disorder: study in 174 patients. *PLoS ONE*, **2014**, 9, e89741	3.7	308
78	Low cerebrospinal fluid concentration of mitochondrial DNA in preclinical Alzheimer disease. *Annals of Neurology*, **2013**, 74, 655-68	9.4	129
77	A pan-European study of the C9orf72 repeat associated with FTLD: geographic prevalence, genomic instability, and intermediate repeats. *Human Mutation*, **2013**, 34, 363-73	4.7	208
76	Atypical neuropathological sCJD-MM phenotype with abundant white matter Kuru-type plaques sparing the cerebellar cortex. *Neuropathology*, **2013**, 33, 204-8	2	6
75	Distinct patterns of APP processing in the CNS in autosomal-dominant and sporadic Alzheimer disease. *Acta Neuropathologica*, **2013**, 125, 201-13	14.3	81
74	A preliminary study of the whole-genome expression profile of sporadic and monogenic early-onset Alzheimer's disease. *Neurobiology of Aging*, **2013**, 34, 1772-8	5.6	59
73	Distinctive age-related temporal cortical thinning in asymptomatic granulin gene mutation carriers. *Neurobiology of Aging*, **2013**, 34, 1462-8	5.6	14

72	Neurodegenerative disease status and post-mortem pathology in idiopathic rapid-eye-movement sleep behaviour disorder: an observational cohort study. *Lancet Neurology, The*, **2013**, 12, 443-53	24.1	472
71	Neuroimaging and biochemical markers in the three variants of primary progressive aphasia. *Dementia and Geriatric Cognitive Disorders*, **2013**, 35, 106-17	2.6	43
70	Cognitive reserve proxies relate to gray matter loss in cognitively healthy elderly with abnormal cerebrospinal fluid amyloid-β levels. *Journal of Alzheimer's Disease*, **2013**, 35, 715-26	4.3	33
69	Donepezil treatment stabilizes functional connectivity during resting state and brain activity during memory encoding in Alzheimer's disease. *Journal of Clinical Psychopharmacology*, **2013**, 33, 199-205	1.7	32
68	Decreased striatal dopamine transporter uptake in the non-fluent/agrammatic variant of primary progressive aphasia. *European Journal of Neurology*, **2013**, 20, 1459-e126	6	6
67	Rare variants in calcium homeostasis modulator 1 (CALHM1) found in early onset Alzheimer's disease patients alter calcium homeostasis. *PLoS ONE*, **2013**, 8, e74203	3.7	22
66	Evolving brain functional abnormalities in PSEN1 mutation carriers: a resting and visual encoding fMRI study. *Journal of Alzheimer's Disease*, **2013**, 36, 165-75	4.3	15
65	"Preclinical" MSA in definite Creutzfeldt-Jakob disease. *Neuropathology*, **2012**, 32, 158-63	2	14
64	Applying the new research diagnostic criteria: MRI findings and neuropsychological correlations of prodromal AD. *International Journal of Geriatric Psychiatry*, **2012**, 27, 127-34	3.9	33
63	Serum progranulin levels in patients with frontotemporal lobar degeneration and Alzheimer's disease: detection of GRN mutations in a Spanish cohort. *Journal of Alzheimer's Disease*, **2012**, 31, 581-91	4.3	29
62	Distinct functional activity of the precuneus and posterior cingulate cortex during encoding in the preclinical stage of Alzheimer's disease. *Journal of Alzheimer's Disease*, **2012**, 31, 517-26	4.3	39
61	Hirano body-rich subtypes of Creutzfeldt-Jakob disease. *Neuropathology and Applied Neurobiology*, **2012**, 38, 153-61	5.2	6
60	Rapidly progressive dementia: experience in a tertiary care medical center. *Alzheimer Disease and Associated Disorders*, **2012**, 26, 267-71	2.5	35
59	Inherited prion disease with 4-octapeptide repeat insertion linked to valine at codon 129. *Brain*, **2012**, 135, e212	11.2	7
58	Breakpoint sequence analysis of an APP locus duplication associated with autosomal dominant Alzheimer's disease and severe cerebral amyloid angiopathy. *Journal of Alzheimer's Disease*, **2012**, 28, 303-8	4.3	8
57	Cerebrospinal fluid biomarker supported diagnosis of Creutzfeldt-Jakob disease and rapid dementias: a longitudinal multicentre study over 10 years. *Brain*, **2012**, 135, 3051-61	11.2	102
56	Identifying earlier Alzheimer's disease: insights from the preclinical and prodromal phases. *Neurodegenerative Diseases*, **2012**, 10, 158-60	2.3	12
55	PSEN1 mutation carriers present lower cerebrospinal fluid amyoid-β42 levels than sporadic early-onset Alzheimer's disease patients but no differences in neuronal injury biomarkers. *Journal of Alzheimer's Disease*, **2012**, 30, 605-16	4.3	6

54	The amyloid-β isoform pattern in cerebrospinal fluid in familial PSEN1 M139T- and L286P-associated Alzheimer's disease. *Molecular Medicine Reports*, **2012**, 5, 1111-5	2.9	14
53	PICOGEN: Five years experience with a genetic counselling program for dementia. *Neurología (English Edition)*, **2011**, 26, 143-149	0.4	
52	Cognitively preserved subjects with transitional cerebrospinal fluid β-amyloid 1-42 values have thicker cortex in Alzheimer's disease vulnerable areas. *Biological Psychiatry*, **2011**, 70, 183-90	7.9	75
51	A novel PSEN1 gene mutation (L235R) associated with familial early-onset Alzheimer's disease. *Neuroscience Letters*, **2011**, 496, 40-2	3.3	11
50	Focusing on atypical symptoms for improved diagnosis of early-onset Alzheimer's disease. *Future Neurology*, **2011**, 6, 575-578	1.5	3
49	Cerebrospinal fluid biomarkers and memory present distinct associations along the continuum from healthy subjects to AD patients. *Journal of Alzheimer's Disease*, **2011**, 23, 319-26	4.3	56
48	PICOGEN: five years experience with a genetic counselling program for dementia. *Neurología*, **2011**, 26, 143-9	1.4	19
47	Association between cerebrospinal fluid tau and brain atrophy is not related to clinical severity in the Alzheimer's disease continuum. *Psychiatry Research - Neuroimaging*, **2011**, 192, 140-6	2.9	15
46	Different profiles of Alzheimer's disease cerebrospinal fluid biomarkers in controls and subjects with subjective memory complaints. *Journal of Neural Transmission*, **2011**, 118, 259-62	4.3	41
45	Neuropsychological profile of prodromal Alzheimer's disease (Prd-AD) and their radiological correlates. *Archives of Gerontology and Geriatrics*, **2011**, 52, 190-6	4	20
44	Cerebrospinal fluid biomarkers in Alzheimer's disease families with PSEN1 mutations. *Neurodegenerative Diseases*, **2011**, 8, 202-7	2.3	23
43	Clinical features and APOE genotype of pathologically proven early-onset Alzheimer disease. *Neurology*, **2011**, 76, 1720-5	6.5	91
42	New mutation in the PSEN1 (E120G) gene associated with early onset Alzheimer's disease. *Neurología (English Edition)*, **2010**, 25, 13-16	0.4	
41	Cognitive reserve modulates task-induced activations and deactivations in healthy elders, amnestic mild cognitive impairment and mild Alzheimer's disease. *Cortex*, **2010**, 46, 451-61	3.8	104
40	Genetic screening of Alzheimer's disease genes in Iberian and African samples yields novel mutations in presenilins and APP. *Neurobiology of Aging*, **2010**, 31, 725-31	5.6	162
39	Clinical, neuropathologic, and biochemical profile of the amyloid precursor protein I716F mutation. *Journal of Neuropathology and Experimental Neurology*, **2010**, 69, 53-9	3.1	37
38	Increased cortical thickness and caudate volume precede atrophy in PSEN1 mutation carriers. *Journal of Alzheimer's Disease*, **2010**, 22, 909-22	4.3	103
37	Nueva mutación en el gen PSEN1 (E120G) asociada a enfermedad de Alzheimer de inicio precoz. *Neurología*, **2010**, 25, 13-16	1.4	7

36	The memory alteration test (M@T) discriminates between subjective memory complaints, mild cognitive impairment and Alzheimer's disease. *Archives of Gerontology and Geriatrics*, **2010**, 50, 171-4	4	29
35	A novel PSEN1 mutation (K239N) associated with Alzheimer's disease with wide range age of onset and slow progression. *European Journal of Neurology*, **2010**, 17, 994-6	6	17
34	Voxel based morphometry features and follow-up of amnestic patients at high risk for Alzheimer's disease conversion. *International Journal of Geriatric Psychiatry*, **2009**, 24, 875-84	3.9	15
33	Cerebrospinal fluid biomarkers in human genetic transmissible spongiform encephalopathies. *Journal of Neurology*, **2009**, 256, 1620-8	5.5	68
32	Interactions of cognitive reserve with regional brain anatomy and brain function during a working memory task in healthy elders. *Biological Psychology*, **2009**, 80, 256-9	3.2	65
31	Atrofia cortical posterior. Perfil neuropsicol□gico y diferencias con la enfermedad de Alzheimer t□pica. *Revista De Neurologia*, **2009**, 48, 178	24	3
30	Validez discriminativa y asociaci□ del test minimental (MMSE) y del test de alteraci□ de memoria (T@M) con una bater□ neuropsicol□gica en pacientes con deterioro cognitivo leve amn□sico y enfermedad de Alzheimer. *Revista De Neurologia*, **2009**, 49, 169	24	4
29	Naming is associated with left temporal pole metabolite levels in neurodegenerative diseases. *Dementia and Geriatric Cognitive Disorders*, **2008**, 25, 212-7	2.6	9
28	First demonstrated de novo insertion in the prion protein gene in a young patient with dementia. *Journal of Neurology, Neurosurgery and Psychiatry*, **2008**, 79, 845-6	5.5	10
27	Molecular evidence of founder effects of fatal familial insomnia through SNP haplotypes around the D178N mutation. *Neurogenetics*, **2008**, 9, 109-18	3	12
26	Clinicopathological and genetic correlates of frontotemporal lobar degeneration and corticobasal degeneration. *Journal of Neurology*, **2008**, 255, 488-94	5.5	36
25	Screening for amnestic mild cognitive impairment and early Alzheimer's disease with M@T (Memory Alteration Test) in the primary care population. *International Journal of Geriatric Psychiatry*, **2007**, 22, 294-304	3.9	82
24	CSF analysis in patients with sporadic CJD and other transmissible spongiform encephalopathies. *European Journal of Neurology*, **2007**, 14, 121-4	6	53
23	A novel MAPT mutation (P301T) associated with familial frontotemporal dementia. *European Journal of Neurology*, **2007**, 14, e9-10	6	13
22	A novel mutation in the PSEN1 gene (L286P) associated with familial early-onset dementia of Alzheimer type and lobar haematomas. *European Journal of Neurology*, **2007**, 14, 1409-12	6	17
21	Late-onset frontotemporal dementia associated with a novel PGRN mutation. *Journal of Neural Transmission*, **2007**, 114, 1051-4	4.3	13
20	Brain tau expression and correlation with the H1/H1 tau genotype in frontotemporal lobar degeneration patients. *Journal of Neural Transmission*, **2007**, 114, 1585-8	4.3	6
19	Influence of timing on CSF tests value for Creutzfeldt-Jakob disease diagnosis. *Journal of Neurology* , **2007**, 254, 901-6	5.5	66

18	Cortical brain metabolism as measured by proton spectroscopy is related to memory performance in patients with amnestic mild cognitive impairment and Alzheimer's disease. *Dementia and Geriatric Cognitive Disorders*, **2007**, 24, 274-9	2.6	34
17	Longitudinal study of amnesic patients at high risk for Alzheimer's disease: clinical, neuropsychological and magnetic resonance spectroscopy features. *Dementia and Geriatric Cognitive Disorders*, **2007**, 24, 402-10	2.6	35
16	MAPT gene duplications are not a cause of frontotemporal lobar degeneration. *Neuroscience Letters*, **2007**, 424, 61-5	3.3	14
15	From progressive nonfluent aphasia to corticobasal syndrome: a case report of corticobasal degeneration. *Neurocase*, **2006**, 12, 355-9	0.8	22
14	Ancestral origins of the prion protein gene D178N mutation in the Basque Country. *Human Genetics* , **2005**, 117, 61-9	6.3	7
13	Discrepancies in the clinical utility of the 14-3-3 protein for the diagnosis of sporadic Creutzfeldt-Jakob disease. *Archives of Neurology*, **2004**, 61, 604		2
12	Clinical and genetic features of human prion diseases in Catalonia: 1993-2002. *European Journal of Neurology*, **2004**, 11, 649-55	6	22
11	CSF 14-3-3 protein assay and MRI as prognostic markers in patients with a clinically isolated syndrome suggestive of MS. *Journal of Neurology*, **2004**, 251, 1278-9	5.5	24
10	Anti-Tr antibodies as markers of paraneoplastic cerebellar degeneration and Hodgkin's disease. *Neurology*, **2003**, 60, 230-4	6.5	246
9	Analysis of the exon 1 polymorphism in the Tau gene in transmissible spongiform encephalopathies. *Journal of Neurology*, **2002**, 249, 938-9	5.5	4
8	Phosphorylated tau in cerebrospinal fluid as a marker for Creutzfeldt-Jakob disease. *Journal of Neurology, Neurosurgery and Psychiatry*, **2002**, 73, 79-81	5.5	30
7	14-3-3 Protein isoforms and atypical patterns of the 14-3-3 assay in the diagnosis of Creutzfeldt-Jakob disease. *Neuroscience Letters*, **2002**, 320, 69-72	3.3	24
6	14-3-3 protein in the CSF as prognostic marker in early multiple sclerosis. *Neurology*, **2001**, 57, 722-4	6.5	59
5	Autoantibodies against the prion protein in individuals with PRNP mutations		1
4	Brain functional network integrity sustains cognitive function despite atrophy in presymptomatic genetic frontotemporal dementia		2
3	AETIONOMY, a Cross-Sectional Study Aimed at validating a new taxonomy of Neurodegenerative Diseases: Study design and subject characteristics		2
2	Common variants in Alzheimer disease: Novel association of six genetic variants with AD and risk stratification by polygenic risk scores		9
1	Analysis of brain atrophy and local gene expression in genetic frontotemporal dementia		2